From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma

A. Thomas, A. Rajan, A. Lopez-Chavez, Y. Wang, G. Giaccone

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Although tumor molecular-profile-directed therapy appears promising in early clinical studies, there are many practical challenges to its successful clinical application in non-small-cell lung cancer (NSCLC). These challenges may be broadly classified as those relating to tumor (heterogeneity), tissue (acquisition and processing), testing (assays for molecular profiling) and trials (clinical evaluation of molecular markers and drugs). Strategies to overcome these challenges include (i) understanding the biological basis of tumor heterogeneity and of carcinogenesis in the large subset of patients with no currently evident driver events; (ii) technological advances in minimally invasive acquisition of tumor and nextgeneration sequencing (NGS) which would enable single-platform analysis of molecular alterations in limited tissue at a reasonable turnaround time (TAT); (iii) deliberation in early stages of drug development as well as clinical trial design to identify, validate and assess the clinical utility of biomarkers in conjunction with drugs and (iv) collaboration to improve understanding of and accrual to trials enrolling patients with rare molecular alterations.

Original languageEnglish (US)
Article numbermds478
Pages (from-to)577-585
Number of pages9
JournalAnnals of Oncology
Issue number3
StatePublished - Mar 2013
Externally publishedYes


  • Molecular profiling
  • Next-generation sequencing
  • Non-small-cell lung cancer
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'From targets to targeted therapies and molecular profiling in non-small cell lung carcinoma'. Together they form a unique fingerprint.

Cite this